Endoscopic "gut reset" procedure prevents weight rebound after stopping Ozempic and Wegovy

A minimally invasive procedure called duodenal mucosal resurfacing helps patients keep weight off after stopping Ozempic or Wegovy by resetting gut metabolism.

By: AXL Media

Published: Apr 23, 2026, 8:32 AM EDT

Source: Information for this report was sourced from Digestive Disease Week (DDW)

Endoscopic "gut reset" procedure prevents weight rebound after stopping Ozempic and Wegovy - article image
Endoscopic "gut reset" procedure prevents weight rebound after stopping Ozempic and Wegovy - article image

Addressing the Ozempic Rebound Effect

As GLP-1 medications like Ozempic, Wegovy, and Mounjaro become staples in obesity management, a major clinical challenge has emerged: the "rebound" effect. Approximately 70% of users regain a substantial portion of their lost weight within 18 months of stopping the medication. However, a breakthrough procedure known as duodenal mucosal resurfacing (DMR) may offer a solution. According to research presented at Digestive Disease Week® (DDW) 2026, this outpatient procedure effectively "resets" the metabolism by renewing the lining of the small intestine, allowing patients to maintain their weight loss results without the need for lifelong pharmaceutical intervention.

The Science of Duodenal Mucosal Resurfacing

DMR is an investigational endoscopic treatment that targets the duodenum, the first section of the small intestine. Over time, diets high in sugar and fat can damage this mucosal layer, altering the hormonal signals that regulate insulin resistance and satiety. The procedure uses controlled heat to ablate (burn) the unhealthy lining, which then heals and regenerates into healthier tissue. Lead author Dr. Shelby Sullivan, director of the Endoscopic Bariatric and Metabolic Program at Dartmouth Health, explained that this renewal process triggers a lasting metabolic reset, essentially stabilizing the body at its new, lower weight.

Trial Evidence: Maintaining the Loss

The findings come from the REMAIN-1 trial, a randomized, sham-controlled study. Researchers tracked 45 participants who had previously lost an average of 40 pounds using tirzepatide. Upon stopping the drug, one group received the DMR treatment while the other received a "sham" procedure. After six months, the difference was stark: the control group regained significantly more weight—nearly twice as much as those who received the resurfacing. Most impressively, patients who received a more extensive version of the resurfacing regained only about 7 pounds total, successfully preserving over 80% of their initial weight loss.

Categories

Topics

Related Coverage